Omnicell downgraded to Neutral from Buy at BofA

BofA analyst Allen Lutz downgraded Omnicell (OMCL) to Neutral from Buy with a price target of $57, up from $44. The market is pricing in a clear return to growth for Omnicell’s Product business with shares up 30%, notes the analyst. However, while product extensions like XTAmplify can help drive incremental sales, visibility into growth is low, the analyst tells investors.